New Strategies to Overcome Temozolomide Resistance in Glioblastoma
Abstract：Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. The combination of surgery, radiotherapy, and temozolomide (TMZ) chemotherapy remains the standard treatment, but the median survival time of patients is still only 12-15 months [1]. TMZ, as a first-line chemotherapeutic agent, exerts its antitumor effect by inducing DNA damage, but drug resistance has become the main cause of clinical treatment failure [2-3]. The role of epigenetic regulation mediated by super-enhancers (SE) in tumor drug resistance has attracted increasing attention [4].
Machine-generated Keywords：
Publication Date：2025-11-20
Online Publishing Date：2026-01-04(First online date of this platform, not the publication date of the document)
Pages：1( 691 )